GlobeNewswire BiotechnologyCodex · 实盘不做把握 3/10
北京时间·🕒 发布 08-03 19:30:00时区推断·⟳ 抓取 08-03 19:31:07·⚡ 决策 08-04 09:39:13 +14h08m·84.3 天前
ARS Pharmaceuticals预告8月13日召开战略重点更新及二季度业绩电话会
本条只预告电话会时间和议程，未披露二季度业绩、指引或产品商业化新数据。
📄 原文GlobeNewswire Biotechnology↗ 原文
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedi…
不做 ARS Pharmaceuticals（SPRY.US）
只是业绩电话会和战略更新预告，未披露二季度数字、指引或商业化增量，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 medium ↗
消息传播链
- 公司发布8月13日电话会预告，尚未披露业绩数字。市场反应:SPRY当日收涨6.43%，但本条本身不解释基本面增量。
关键理由
- 本条只预告电话会时间和议程，未披露二季度业绩、指引或产品商业化新数据。
主要风险
- 8月13日正式业绩和战略更新才可能形成新决策。
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,839 字
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strategic priorities and report second quarter 2026 financial results.
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
ARS Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com
ARS Media Contact:
Christy Curran, Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
ARS Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com
ARS Media Contact:
Christy Curran, Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。